S'abonner

Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study - 26/11/20

Doi : 10.1016/S1473-3099(20)30630-7 
Nicholas C Grassly, DPhil a, , Margarita Pons-Salort, PhD a, Edward P K Parker, PhD b, Peter J White, PhD a, Neil M Ferguson, DPhil a
on behalf of the

Imperial College COVID-19 Response Team

  Members of the Imperial College COVID-19 Response Team are listed at the end of the Article
Kylie Ainslie, Marc Baguelin, Samir Bhatt, Adhiratha Boonyasiri, Nick Brazeau, Lorenzo Cattarino, Helen Coupland, Zulma Cucunuba, Gina Cuomo-Dannenburg, Amy Dighe, Christl Donnelly, Sabine L van Elsland, Richard FitzJohn, Seth Flaxman, Keith Fraser, Katy Gaythorpe, Will Green, Arran Hamlet, Wes Hinsley, Natsuko Imai, Edward Knock, Daniel Laydon, Thomas Mellan, Swapnil Mishra, Gemma Nedjati-Gilani, Pierre Nouvellet, Lucy Okell, Manon Ragonnet-Cronin, Hayley A Thompson, H. Juliette T Unwin, Michaela Vollmer, Erik Volz, Caroline Walters, Yuanrong Wang, Oliver J Watson, Charles Whittaker, Lilith Whittles, Xiaoyue Xi

a MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK 
b The Vaccine Centre, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK 

* Correspondence to: Dr Nicholas C Grassly, MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London W2 1PG, UK MRC Centre for Global Infectious Disease Analysis Department of Infectious Disease Epidemiology Imperial College London London W2 1PG UK

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Background

WHO has called for increased testing in response to the COVID-19 pandemic, but countries have taken different approaches and the effectiveness of alternative strategies is unknown. We aimed to investigate the potential impact of different testing and isolation strategies on transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Methods

We developed a mathematical model of SARS-CoV-2 transmission based on infectiousness and PCR test sensitivity over time since infection. We estimated the reduction in the effective reproduction number (R) achieved by testing and isolating symptomatic individuals, regular screening of high-risk groups irrespective of symptoms, and quarantine of contacts of laboratory-confirmed cases identified through test-and-trace protocols. The expected effectiveness of different testing strategies was defined as the percentage reduction in R. We reviewed data on the performance of antibody tests reported by the Foundation for Innovative New Diagnostics and examined their implications for the use of so-called immunity passports.

Findings

If all individuals with symptoms compatible with COVID-19 self-isolated and self-isolation was 100% effective in reducing onwards transmission, self-isolation of symptomatic individuals would result in a reduction in R of 47% (95% uncertainty interval [UI] 32–55). PCR testing to identify SARS-CoV-2 infection soon after symptom onset could reduce the number of individuals needing to self-isolate, but would also reduce the effectiveness of self-isolation (around 10% would be false negatives). Weekly screening of health-care workers and other high-risk groups irrespective of symptoms by use of PCR testing is estimated to reduce their contribution to SARS-CoV-2 transmission by 23% (95% UI 16–40), on top of reductions achieved by self-isolation following symptoms, assuming results are available at 24 h. The effectiveness of test and trace depends strongly on coverage and the timeliness of contact tracing, potentially reducing R by 26% (95% UI 14–35) on top of reductions achieved by self-isolation following symptoms, if 80% of cases and contacts are identified and there is immediate testing following symptom onset and quarantine of contacts within 24 h. Among currently available antibody tests, performance has been highly variable, with specificity around 90% or lower for rapid diagnostic tests and 95–99% for laboratory-based ELISA and chemiluminescent assays.

Interpretation

Molecular testing can play an important role in prevention of SARS-CoV-2 transmission, especially among health-care workers and other high-risk groups, but no single strategy will reduce R below 1 at current levels of population immunity. Immunity passports based on antibody tests or tests for infection face substantial technical, legal, and ethical challenges.

Funding

UK Medical Research Council.

Le texte complet de cet article est disponible en PDF.

Plan


© 2020  The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 20 - N° 12

P. 1381-1389 - décembre 2020 Retour au numéro
Article précédent Article précédent
  • Bats and viruses
  • Vikram Misra
| Article suivant Article suivant
  • Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
  • The National SARS-CoV-2 Serology Assay Evaluation Group, Mark Ainsworth, Monique Andersson, Kathryn Auckland, J Kenneth Baillie, Eleanor Barnes, Sally Beer, Amy Beveridge, Sagida Bibi, Luke Blackwell, Martyna Borak, Abbie Bown, Tim Brooks, Nicola A Burgess-Brown, Susana Camara, Matthew Catton, Kevin K. Chau, Thomas Christott, Elizabeth Clutterbuck, Jesse Coker, Richard J Cornall, Stuart Cox, David Crawford-Jones, Derrick W Crook, Silvia D’Arcangelo, Wanwisa Dejnirattsai, Julie M M Dequaire, Stavros Dimitriadis, Kate E Dingle, George Doherty, Christina Dold, Tao Dong, Susanna J Dunachie, Daniel Ebner, Marc Emmenegger, Alexis Espinosa, David W Eyre, Rory Fairhead, Shayan Fassih, Conor Feehily, Sally Felle, Alejandra Fernandez-Cid, Maria Fernandez Mendoza, Thomas H Foord, Thomas Fordwoh, Deborah Fox McKee, John Frater, Veronica Gallardo Sanchez, Nick Gent, Dominique Georgiou, Christopher J Groves, Bassam Hallis, Peter M Hammond, Stephanie B. Hatch, Heli J Harvala, Jennifer Hill, Sarah J Hoosdally, Bryn Horsington, Alison Howarth, Tim James, Katie Jeffery, Elizabeth Jones, Anita Justice, Fredrik Karpe, James Kavanagh, David S Kim, Richard Kirton, Paul Klenerman, Julian C Knight, Leonidas Koukouflis, Andrew Kwok, Ullrich Leuschner, Robert Levin, Aline Linder, Teresa Lockett, Sheila F Lumley, Spyridoula Marinou, Brian D Marsden, Jose Martinez, Lucas Martins Ferreira, Lara Mason, Philippa C Matthews, Alexander J Mentzer, Alexander Mobbs, Juthathip Mongkolsapaya, Jordan Morrow, Shubhashish M M Mukhopadhyay, Matthew J Neville, Sarah Oakley, Marta Oliveira, Ashley Otter, Kevin Paddon, Jordan Pascoe, Yanchun Peng, Elena Perez, Prem K Perumal, Timothy E A Peto, Hayleah Pickford, Rutger J Ploeg, Andrew J Pollard, Anastasia Richardson, Thomas G Ritter, David J Roberts, Gillian Rodger, Christine S Rollier, Cathy Rowe, Justine K Rudkin, Gavin Screaton, Malcolm G Semple, Alex Sienkiewicz, Laura Silva-Reyes, Donal T Skelly, Alberto Sobrino Diaz, Lizzie Stafford, Lisa Stockdale, Nicole Stoesser, Teresa Street, David I Stuart, Angela Sweed, Adan Taylor, Hannah Thraves, Hoi P Tsang, Marije K Verheul, Richard Vipond, Timothy M Walker, Susan Wareing, Yolanda Warren, Charlie Wells, Clare Wilson, Kate Withycombe, Rebecca K Young

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.